News

Arrivo was founded by Steve Butts, Bill Wofford, Dr. Michael Ackermann and Dr. Jed Black, and located in North Carolina’s Research Triangle Park region. Mr. Butts and Mr.

It is intended that ABLS Capital, LLC, which includes Allied Minds, Woodford Investment Management and Invesco Asset Management among its investors, will fund 80% of this phase of

These findings on BAX 930 were presented during a poster session at the 62nd annual Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and

About 500 patients will be enrolled in the randomized, double-blind, placebo-controlled phase 3 study, dubbed Cascade, which will assess 33A in combination with azacitidine (Vidaza) or decitabine (Dacogen)

The 15-member panel of the Endocrinologic and Metabolic Drugs Advisory Committee voted 12 to 2 (1 panelist did not vote due to travel) to approve the combination. Two

ALKS 4230, which was formerly referred to as RDB 1450, a novel selective effector cell activator protein designed to preferentially bind and signal through the intermediate affinity interleukin-2

The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies. Using clinical trial data from the past

The lead, a reversible BTK inhibitor, offers exciting potential to treat Chronic Lymphocytic Leukaemia (CLL) patients who have become resistant to the gold standard therapy, Imbruvica (ibrutinib). This

IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba) and liraglutide (Victoza) for the treatment of adults with type 2 diabetes. Based on the data